Yes, I can venture a response. From my understanding of the process, one of the reasons it took a long time was that the legislation requires that the country first express its desire to purchase the drugs from the Canadian company, which is a bit of a catch-22 situation, because in order for that to happen, the company has to be able to take part in the national tender process, which would require the compulsory licence.
I think one of the greatest advantages of the amendment to this legislation is that there would be a sort of one-licence submission, whereby the company would not require a country to come forward and explicitly express interest in order to be able to export these drugs. That would greatly reduce the bureaucratic impediments in future.